TABLE 3.
JAMs in cancers.
| Protein | Cancer | Final effect |
|---|---|---|
| JAM-A | Breast cancer, anaplastic thyroid carcinoma, and colorectal cancer | Inhibits invasion and migration |
| Naik et al. (2008) | ||
| Naik and Naik (2008) | ||
| McSherry et al. (2009) | ||
| McSherry et al. (2011) | ||
| Bednarek et al. (2020) | ||
| Imbert et al. (2012) | ||
| Vences-Catalán et al. (2021) | ||
| Cao et al. (2014) | ||
| Orlandella et al. (2019) | ||
| Lampis et al. (2021) | ||
| Nasopharyngeal carcinoma, head and neck squamous cell carcinoma, uterine cervical adenocarcinoma, renal cancer, gastric cancer, and multiple myeloma | Induces proliferation, migration, and invasiveness | |
| Tian et al. (2015) | ||
| Dai et al. (2021) | ||
| Kakiuchi et al. (2021) | ||
| Murakami et al. (2021) | ||
| Gutwein et al. (2009) | ||
| Huang et al. (2014) | ||
| Solimando et al. (2018) | ||
| JAM-B | Glioma and pancreatic cancer | Promotes progression and invasion |
| Qi et al. (2013) | ||
| Qi et al. (2014) | ||
| Zhang et al. (2020) | ||
| JAM-C | Ovarian cancer, melanoma, and fibrosarcoma metastasis | Promotes cell proliferation and migration |
| Sheng et al. (2020) | ||
| Langer et al. (2011) | ||
| Fuse et al. (2007) | ||
| Renal carcinoma | Suppresses migration | |
| Li N et al. (2018) | ||
| JAML | Gastric cancer | Promotes migration and proliferation |
| Fang et al. (2021) |